United Therapeutics Corporation Defined Contribution Plan, Cost
United Therapeutics Corporation (UTHR) reported Defined Contribution Plan, Cost of $3.00 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-24.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2015-02-24
- United Therapeutics Corporation defined contribution plan, cost for fiscal 2014 was $3.00M, a 20.00% increase from fiscal 2013.
- United Therapeutics Corporation defined contribution plan, cost for fiscal 2013 was $2.50M, a 19.05% increase from fiscal 2012.
- United Therapeutics Corporation defined contribution plan, cost for fiscal 2012 was $2.10M, a 23.53% increase from fiscal 2011.
- United Therapeutics Corporation defined contribution plan, cost for fiscal 2011 was $1.70M, a 21.43% increase from fiscal 2010.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2014-12-31 | $3.00M 10-K · filed 2015-02-24 |
| 2013-12-31 | $2.50M 10-K · filed 2015-02-24 |
| 2012-12-31 | $2.10M 10-K · filed 2015-02-24 |
| 2011-12-31 | $1.70M 10-K · filed 2014-02-25 |
| 2010-12-31 | $1.40M 10-K · filed 2013-02-26 |
| 2009-12-31 | $847.00K 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |